We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 29, 2022

Divergent Clinical Outcomes of the TLPLDC Vaccine in Preventing Melanoma Recurrence and the Impact of the Dendritic Cell Collection Methodology

Cancer Immunology, Immunotherapy: CII


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Immunology, Immunotherapy: CII
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
Cancer Immunol. Immunother. 2022 Sep 01;[EPub Ahead of Print], AM Adams, EL Carpenter, GT Clifton, TJ Vreeland, RC Chick, AE O'Shea, PM McCarthy, PM Kemp Bohan, AT Hickerson, FA Valdera, A Tiwari, DF Hale, JR Hyngstrom, AC Berger, JW Jakub, JJ Sussman, MF Shaheen, X Yu, TE Wagner, MB Faries, GE Peoples

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading